Clinical trial
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
NCT03046251 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
- Lead sponsor
- State University of New York at Buffalo
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 31, 2015
- Completion date
- December 31, 2023
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.